2024-06-29-Clarivate-Where_pharma_is_investing_for_the_future_of_medicine——Biopharma_deal_making_in_2024_35页_5mb

Summary of "Where Pharma is Investing for the Future of Medicine"

Core Content

The biopharma deal-making landscape in 2023 showed a significant rebound after a challenging 2022, with M&A activity increasing by 80% in value compared to the previous year. The total value of M&A and partnering deals reached $217.69bn, the highest ever recorded, despite a decline in the number of transactions.

Main Points

• M&A Activity Recovery:

  • M&A activity in 2023 reached $70.9bn, up from $60.8bn in 2022.
  • The number of completed M&A transactions increased to 1,380 in 2023, though still below the peak in 2019-2021.
  • Q4 2023 alone exceeded the total 2022 M&A value, signaling a strong recovery.

• Strategic Focus:

  • Life science companies are prioritizing innovation in key therapeutic areas and divesting from less promising ones.
  • There is a growing interest in AI/ML, ADCs, and polyspecific antibodies as they offer potential for disruptive innovation.

• Regulatory Challenges:

  • The FTC's increased scrutiny of M&A deals has led to delays, particularly in large transactions.
  • Despite these challenges, some major deals were completed, such as Pfizer's acquisition of Seagen for $43bn and Amgen's acquisition of Horizon Therapeutics for $27.8bn.

• Big Pharma's Strategic Moves:

  • Big pharma continues to be the primary driver of M&A activity, with 69% of M&A investment in 2023 coming from these companies.
  • Companies are focusing on securing inorganic growth through strategic acquisitions, especially in areas like oncology, neuroscience, and immunology.

• Neuroscience M&A Renaissance:

  • There has been a renewed interest in neuroscience due to recent approvals of disease-modifying Alzheimer's drugs and advancements in treating neuropsychiatric conditions.
  • Bristol-Myers Squibb's $14bn acquisition of Karuna Therapeutics is a major example, targeting schizophrenia and Alzheimer's-related psychosis.

• ADCs Dominating Deals:

  • ADCs (Antibody Drug Conjugates) continue to be a major focus in M&A and partnering deals.
  • Nearly one-quarter of the $1bn-plus deals in 2023 involved ADCs.
  • MSD's $22bn deal with Daiichi Sankyo for three ADCs is the largest in the year, highlighting the importance of these therapies in oncology.

• Polyspecific Antibodies:

  • These are gaining traction due to their potential to treat multiple diseases with a single molecule.
  • Companies are investing in this area to explore new therapeutic possibilities.

• Partnerships and Collaborations:

  • Partnerships are becoming more common as companies seek to access innovative technologies and reduce reliance on capital markets.
  • Smaller biotechs are increasingly turning to partnerships for funding and development support.

Key Deals in 2023

Target	Acquirer	Focus	Date	Potential Value ($m)
Seagen Inc	Pfizer Inc	Oncology	12/14/2023	43,000
Horizon Therapeutics plc	Amgen	Inflammation	10/06/2023	27,800
Prometheus Biosciences Inc	MSD	Immunology	06/16/2023	10,800
Reata Pharmaceuticals Inc	Biogen Inc	Neurology	09/26/2023	7,300
Telavant Holdings Inc	Roche	Inflammatory bowel disease	12/14/2023	7,250
Iveric Bio Inc	Astellas Pharma Inc	Ophthalmology	07/11/2023	5,900
Abcam	Danaher	Protein consumables	12/06/2023	5,700
Chinook Therapeutics Inc	Novartis	Kidney disease	08/11/2023	3,500
NuVasive Inc	Globus Medical	Musculoskeletal	04/27/2023	3,100
Olink Holding A	Thermo Fisher Scientific Inc	Proteomics discovery and development	10/31/2023	3,100

Major Trends

• Shift to Biologics:

  • Companies are shifting focus to biologics due to the longer period of price negotiation-free status under the Inflation Reduction Act (IRA) for biologics (13 years) compared to small molecules (9 years).

• FTC Impact:

  • The FTC's new merger guidelines have made large M&A transactions more challenging, with a focus on market concentration and competition.
  • Despite this, some major deals were completed, showing that the industry is adapting to these regulatory pressures.

• AI/ML Integration:

  • AI and machine learning are being increasingly used to accelerate drug discovery and development, with companies like Valo Health partnering with Novo Nordisk to leverage these technologies.

• Future Outlook:

  • The industry is expected to continue its focus on strategic areas such as oncology, neuroscience, and immunology.
  • The trend of fewer but higher-value deals is likely to persist in 2024, with an emphasis on acquiring late-stage assets and platform technologies.

References

• BioWorld data on M&A activity and deal values.
• Clarivate's data and expertise in life sciences and healthcare.
• Details on specific deals and their implications for the biopharma industry.